Skip to main content

Hemorrhagic Shock

2
Pipeline Programs
6
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Arrowhead Pharmaceuticals
1 program
1
Tranexamic AcidPhase 31 trial
Active Trials
NCT03469947Completed200Est. Jul 2024
Defence Therapeutics
Defence TherapeuticsBC - Vancouver
1 program
1
Massive transfusion protocolPhase 1/21 trial
Active Trials
NCT00945542Completed70Est. Dec 2011
Temple Therapeutics
Temple TherapeuticsNetherlands - Geleen
1 program
Advanced Life SupportN/A1 trial
Active Trials
NCT02821364Withdrawn0Est. Dec 2025
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
GlutamineN/A1 trial
Active Trials
NCT01239680Completed5Est. Dec 2013
Arsenal Biosciences
Arsenal BiosciencesCA - South SF
1 program
ResQFoamN/A1 trial
Active Trials
NCT02880163Recruiting40Est. Dec 2026
Innogene Kalbiotech
Innogene KalbiotechSingapore - Singapore
1 program
Hyperosmolar sodium lactatePHASE_31 trial
Active Trials
NCT01433276Completed71Est. Jan 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Arrowhead PharmaceuticalsTranexamic Acid
Innogene KalbiotechHyperosmolar sodium lactate
Defence TherapeuticsMassive transfusion protocol
Arsenal BiosciencesResQFoam
Temple TherapeuticsAdvanced Life Support
City TherapeuticsGlutamine

Clinical Trials (6)

Total enrollment: 386 patients across 6 trials

California Prehospital and In Hospital Antifibrinolytic Therapy Via TXA

Start: Mar 2015Est. completion: Jul 2024200 patients
Phase 3Completed
NCT01433276Innogene KalbiotechHyperosmolar sodium lactate

Efficacy, Safety of Solution Containing Hyperosmolar Sodium Lactate Infusion for Resuscitation of Patients With Hemorrhagic Shock

Start: Jul 2009Est. completion: Jan 201171 patients
Phase 3Completed
NCT00945542Defence TherapeuticsMassive transfusion protocol

The Trauma- Formula-Driven Versus Lab-Guided Study (TRFL Study)

Start: Jul 2009Est. completion: Dec 201170 patients
Phase 1/2Completed

REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam

Start: Aug 2025Est. completion: Dec 202640 patients
N/ARecruiting
NCT02821364Temple TherapeuticsAdvanced Life Support

Philadelphia Immediate Transport in Penetrating Trauma Trial

Start: Feb 2020Est. completion: Dec 20250
N/AWithdrawn

Biological Response of Trauma Patients to Standard Trauma Resuscitation Therapy

Start: Jan 2011Est. completion: Dec 20135 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 386 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.